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Analytical Validation and Biological Evaluation of a
High–Molecular-Weight Adiponectin ELISA
Madhur K. Sinha,1* Traci Songer,1 Qiang Xiao,1 John H. Sloan,1 Jin Wang,1
Shaoquen Ji,1 William E. Alborn,2 Randy A. Davis,2 Michael M. Swarbrick,3
Kimber L. Stanhope,3 Bruce M. Wolfe,4 Peter J. Havel,3 Todd Schraw,5
Robert J. Konrad,2 Philipp E. Scherer,5 and Jehangir S. Mistry1
Background: Of the 3 circulating multimeric forms of
adiponectin, the high–molecular-weight (HMW) form, as
measured by size-exclusion and/or immunoblotting tech-
niques, is a better index of insulin sensitivity for monitor-
ing health and disease than is total adiponectin. We aimed
to develop a simple ELISA to measure HMW adiponectin.
Methods: We pretreated serum or plasma samples with
digestion solution containing proteinase K (Millipore,
ESDS). HMW (Millipore, EZHMWA-64K) and total adi-
ponectin (Millipore, EZHADP-61K) concentrations were
measured in treated and untreated samples, respec-
tively, from 108 individuals and from 20 morbidly obese
patients before and at 1, 3, 6, and 12 months after
gastric-bypass surgery.
Results: The ELISA has a dynamic range of 3–200 g/L
and a detection limit of 0.8 g/L. Intraassay and inter-
assay CVs were <4% and <10%, respectively. Sample-
dilution curves paralleled the calibration curves. Fast
protein liquid chromatography profiles of the protein-
ase K-treated samples revealed predominantly HMW
adiponectin. Values for HMW adiponectin produced
with this method are comparable with those obtained
with Western blot analysis (y 0.77x – 0.15; r 0.96; n
56). Body mass index (BMI)- and sex-related changes
were more pronounced for HMW adiponectin and per-
centage of HMW adiponectin than for total adiponectin.
HMW and total adiponectin increased after bypass
surgery, but changes in HMW adiponectin were more
pronounced and preceded changes in total adiponectin.
Conclusion: This simple, rapid ELISA for HMW adi-
ponectin recognizes the HMW isoform, produces results
closely correlated with those obtained with Western
blotting, and appears to better distinguish BMI-, sex-,
and weight loss–associated differences than assays for
total adiponectin.
© 2007 American Association for Clinical Chemistry
Adiponectin, the only secretory hormone of fat cells that
is paradoxically decreased in obesity (1 ), also has insulin-
sensitizing effects (2–4); all other known adipokines are
increased in obesity and induce insulin resistance (5 ).
Given that adipose tissue is the primary site of adiponec-
tin secretion, the decrease in the production and secretion
of adiponectin with increasing adiposity is an intriguing
phenomenon. Substantial and convincing evidence dem-
onstrates that hypoadiponectinemia is associated with
insulin resistance and obesity, diabetes, and metabolic
syndrome including cardiovascular abnormalities (6, 7).
Dietary, lifestyle, and/or pharmacological interventions
(thiazolidinediones) that improve insulin sensitivity also
increase circulating adiponectin concentrations (8, 9). In
addition, decreased adiponectin could be a risk factor for
the progression of insulin resistance and type 2 diabetes in
healthy individuals, with or without impaired glucose
tolerance (10, 11).
Adiponectin is a 28-kDa protein with a collagen-like
structure; it circulates predominantly in 3 multimeric
forms, i.e., trimer, hexamer, and high–molecular-weight
(HMW)6 multimers (12- and 18-mers), which are evident
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from size-fractionation (gel filtration, velocity gradient,
and gel electrophoresis) and immunoblotting experiments
(5 ). These 3 multimeric adiponectin isoforms have differ-
ent biological activities, with HMW adiponectin probably
being the active form (5, 12, 13). Tonelli et al. (14 ) and
Pajvani et al. (15 ) initially showed that the distribution of
these multimers, particularly as measured by the ratio
of HMW adiponectin to total adiponectin (i.e., percentage
of HMW adiponectin), correlates better with thiazo-
lidinedione-mediated improvement in insulin sensitivity
than does the total adiponectin concentration. Percentage
of HMW adiponectin appears to be a better index of
insulin sensitivity (14, 15) and of metabolic syndrome
trait cluster(s) (16 ).
To measure HMW adiponectin and/or percentage of
HMW adiponectin, most studies have combined size
fractionation and immunoblotting (14–21), a cumbersome
approach that cannot easily be adopted for high-through-
put analyses of several samples. Therefore, we have
developed an ELISA to measure HMW adiponectin in
human serum and plasma samples.
Materials and Methods
study participants
We obtained human serum and/or plasma samples from
4 different sources. In the initial development and valida-
tion of the HMW adiponectin ELISA, plasma (containing
EDTA dibasic sodium salt, 1.5 g/L) and serum samples
from 30 individuals (4 men and 26 women) were obtained
from a commercial source (Bioreclamation). After assay
development, we obtained another 56 plasma samples
from Bioreclamation to compare HMW adiponectin val-
ues obtained with the new ELISA and with Western
blotting; we obtained no biochemical or anthropometric
data on these individuals. In a retrospective study, we
obtained another 108 plasma samples from Bioreclama-
tion and measured HMW adiponectin and total adiponec-
tin to evaluate the effect of body mass index (BMI) and
sex. Table 1 summarizes the anthropometric data for these
individuals. Plasma samples obtained from 20 morbidly
obese patients before and at 1, 3, 6, and 12 months after
Roux-en-Y gastric-bypass surgery were also measured to
evaluate the effect of weight loss on HMW adiponectin as
measured with this new ELISA method. The changes in
body composition, measures of insulin resistance, and the
concentrations of adiponectin and its isoforms that oc-
curred after gastric-bypass surgery have previously been
described (22 ). The Institutional Review Board of the
University of California, Davis, approved the experimen-
tal protocol, and all study individuals provided written
informed consent to participate in this study.
fast protein liquid chromatography analysis
Samples of human serum and plasma (100 L of a 1/5
dilution in sample-digestion buffer, EDGB) were fraction-
ated before and after proteinase K (sample-digestion
solution, ESDS) treatment by size-exclusion fast protein
liquid chromatography (FPLC) on a Superdex 200 10/300
Tricorn column (GE Healthcare). Sample treatment with
the enzyme selectively degrades hexamer and trimer
isoforms without affecting HMW adiponectin. The mobile
phase was 25 mmol/L sodium phosphate, pH 7.5, con-
taining 100 mg/L phenylmethylsulfonyl fluoride, with a
flow rate of 0.5 mL/min and a 0.25-mL fraction size. FPLC
fractions of the enzyme-treated and untreated plasma
sample were then assayed for adiponectin immunoreac-
tivity with the Human Adiponectin ELISA (EZHADP-
61K; Millipore) and Human HMW Adiponectin ELISA
(EZHMWA-64K, Millipore) reagent sets.
western blot analysis
We used Western blotting to measure the trimer, hexamer,
and HMW adiponectin isoforms in 56 human plasma sam-
ples. We first fractionated plasma samples by polyacryl-
amide gel electrophoresis under nondenaturing and nonre-
ducing conditions with a 1.5-mm 4%–20% polyacrylamide
Tris-glycine gel cassette (Invitrogen, EC6028BOX), 10
Novex TrisGlycine SDS Running Buffer (Invitrogen, LC2675;
diluted 1/10), and 2 TrisGlycine SDS Sample Buffer (In-
vitrogen, LC2675) in a XCell SureLock MiniCell (Invitrogen,
EI0001) for 1.5 h at 150 V. We ran SeeBlue Plus2 Pre-Stained
Standard (Invitrogen, LC5925) with each electrophoresis
separation. Proteins were transferred from the gel to a
nitrocellulosemembrane at 100 V for 2 h in aMini Trans-Blot
Table 1. Anthropometric variables for the study individuals.a
Group Sex, n Age, years Race, n Systolic BPb, mmHg Diastolic BP, mmHg BMI, kg/m2
Lean (n  25) M, 17 39.0 (12.3) C, 5 128 (12) 77 (8) 21.56 (1.85)
F, 8 AA, 16
H, 4
Overweight (n  28) M, 12 37.8 (12.0) C, 8 121 (12) 76 (8) 26.79 (1.34)
F, 16 AA, 18
H, 2
Obese (n  55) M, 25 36.9 (10.7) C, 16 126 (14) 79 (7) 35.76 (5.13)
F, 30 AA, 30
H, 9
a Data are presented as the mean (SD) where appropriate.
b BP, blood pressure; C, Caucasian; AA, African American; H, Hispanic; M, Male; F, Female.
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Cell with 200mL/Lmethanol, 2 g/L sodiumdodecyl sulfate
and 40 mL 25Novex Tris-Glycine Transfer Buffer (Invitro-
gen, LC3675) in 760 mL distilled water. After blocking
overnight at 4 °C with Blocker Casein in Tris-buffered
saline (1% by weight Casein Hammersten Grade in Tris-
buffered saline, Kathon as preservative, pH 7.4, Pierce,
37532), we incubated the nitrocellulose membrane in the
same buffer for 1.5 h with mouse antihuman adiponectin
monoclonal antibody labeled with horseradish peroxidase
(1/1000 dilution) (R&D Systems,MAB10651). After washing
away the excess antibody, we added detection reagents 1
and 2 in equal proportions (Amersham/GE Healthcare,
RPN2106V1 and RPN2106V2), incubated the membrane for
1 min, and exposed the membrane for 1–4 min to BioMax
Light Film (Kodak, 869358). We digitally photographed the
immunoblot and quantified the trimer, hexamer, and HMW
adiponectin bands with AlphaImager and AlphaEase FC
software V.4.1.0 (Alpha Innotech).
measurement of total human adiponectin and
hmw adiponectin
We measured total adiponectin in serum and plasma
samples with Millipore’s Human Adiponectin ELISA. We
used the newly developed HMW Adiponectin ELISA to
measure HMW adiponectin. We diluted 20-L serum
samples 1/10 with sample-digestion buffer (Millipore,
EDGB) and pretreated the samples with sample-digestion
solution (Millipore, ESDS) for 2 h at 37 °C. Enzyme-
treated samples were diluted further to 1/20 with 1
sample dilution buffer (Millipore, ESDB) and then as-
sayed for HMW adiponectin with the Human HMW
Adiponectin ELISA. The pairs of antibodies for capture
and detection were different for the total (Millipore,
EZHADP-61K) and HMW (Millipore, EZHMWA-64K)
adiponectin ELISA reagent sets. The calibrator for the
total adiponectin ELISA was pooled human serum cali-
brated against recombinant human adiponectin produced
in mammalian cells (Millipore, 1061-K). We used the same
calibrator for the HMW Adiponectin ELISA after we
corrected for the proportion of HMW adiponectin, as
measured by FPLC analysis.
statistical analysis
We carried out a regression analysis to compare HMW
adiponectin values obtained with the HMW ELISA re-
agent set and with Western blotting. Differences in the
concentrations of total adiponectin and HMW adiponec-
tin between lean, overweight, and obese individuals,
between male and female individuals, and before and
after gastric-bypass surgery were compared by means of
2-tailed Student t-tests under the assumption of unequal
variances. Multivariate analysis was performed by step-
wise regression (Minitab 14; Minitab). BMI was entered as
a response variable, and sex, age, race, diastolic and
systolic blood pressures, total adiponectin, HMW adi-
ponectin, and percentage of HMW adiponectin were
entered as predictor variables. HMW, percentage of
HMW, and total adiponectin values are expressed as the
mean (SE), whereas all other data including those of
anthropometric variables and assay characteristics are
expressed as the mean (SD).
Results
characteristics of the hmw adiponectin assay
The calibration curve for this HMW Adiponectin ELISA
(n  8, Fig. 1A) has a concentration range of 3–200 g/L.
Assay imprecision (CV) ranged between 4% and 8% for
absorbance and was 2% for the back-calculated values,
as evaluated by fixed weighted 5-parameter (asymmetri-
cal) logistic curve fitting (StatLIA software; Brendan Tech-
nologies). This program yielded an assay sensitivity of 0.8
g/L, which is the mean  2 SDs of the minimum
detection limit (n  8). Interassay imprecision (4 assays,
10 samples) and intraassay imprecision (5 results within a
single assay, 8 samples; Table 2) were measured after the
samples had each been pretreated and diluted (1/200 final
dilution). HMW adiponectin values reported in Table 2
are after sample pretreatment and dilution from HMW
adiponectin assays. Intraassay CVs were between 1.0%
and 3.4% for sample HMW adiponectin values between
6.0 g/L and 65.3 g/L. Interassay CVs were between
3.0% and 8.1% for HMW adiponectin values between 13.3
g/L and 61.5 g/L. To evaluate the robustness of the
assay, we analyzed 18 different serum samples on 2
different occasions. We observed no significant differ-
Fig. 1. Evaluation of the HMW Adiponectin ELISA.
(A), calibration curve with mean absorbance values (n 8; f) and an imprecision
profile () of CVs based on the same 8 calibration curves. (B), linearity of the
dilution curves for 10 serum samples after pretreating and diluting the sample;
serial dilutions were with ELISA buffer.
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ences (i.e., P 0.05) in HMW adiponectin values [mean
(SD), 8.7 (4.5) mg/L vs 9.0 (4.8) mg/L] with a mean
difference of 1.6% (7.1%) in the mean values obtained
with the 2 replicate assays. Recovery was evaluated by
adding different concentrations of HMW adiponectin
(obtained from human serum after enzyme digestion and
calibration with the HMW Adiponectin ELISA) to 8
pretreated and diluted samples. The data in the recovery
experiments were expressed as a percentage of the ex-
pected value (basal plus added HMW adiponectin). The
mean recovery was 101.2% (1.9%) for 3.125 g/L, 106.6%
(2.3%) for 25 g/L, and 112.4% (3.1%) for 100 g/L. An
evaluation of the linearity of endogenous HMW adi-
ponectin concentrations in serial dilutions (1/8, 1/4, and
1/2) of 10 initially diluted and pretreated serum samples
yielded values between 95% and 110% of the expected
values (value of a 1/1 dilution times the dilution factor).
The dilution curves were linear for all 8 serum samples
(Fig. 1B) and paralleled the calibration curve. Insulin,
glucagons, leptin, glucagon-like peptide 1, amylin, resis-
tin, acylation-stimulating protein, different interleukins,
interferon , tumor necrosis factor , transforming growth
factor , and plasminogen activator inhibitor 1 diluted in
assay buffer (20–1000 g/L) showed no cross-reactivity
(0.01%) with the HMW Adiponectin ELISA in direct
tests. Values for paired serum (x) and plasma (y) samples
(n  21) showed excellent correlation in the same assay
(y  0.95x  0.23; r  0.99); however, plasma values [7.0
(5.1) mg/L] were slightly but significantly lower [mean
difference, 8.0% (5.7%); P 0.01] than serum values [7.5
(5.3) mg/L].
fplc profiles
Six serum samples with or without proteinase K pretreat-
ment were fractionated by FPLC on a Superdex G-200
column. The total adiponectin ELISA for FPLC fractions
of untreated samples detected 3 distinct peaks for the
HMW, hexamer, and trimer isoforms. These results sug-
gest that the total adiponectin ELISA recognizes all 3
adiponectin multimeric isoforms (Fig. 2A). The HMW
Adiponectin ELISA recognizes all 3 isoforms, but hexam-
ers and trimers are recognized to an appreciably lesser
extent before the simple enzyme pretreatment. After
pretreatment, the HMW adiponectin peak remains unal-
tered, whereas both hexamer and trimer peaks virtually
disappear because of their preferential degradation by the
enzyme (Fig. 2A). The efficacy of the HMW Adiponectin
ELISA for measuring HMW adiponectin can be ascribed
to both this ELISA’s lower sensitivity for recognizing
hexamers and trimers and preferential enzymatic degra-
dation of these 2 isoforms.
Table 2. Interassay and intraassay CVs.
Interassay (n  4) Intraassay (n  5)
Sample no. Mean concentration, g/L CV, % Sample no. Mean concentration, g/L CV, %
1 13.3 4.1 11 6.0 1.0
2 21.2 8.1 12 11.1 1.3
3 23.2 4.1 13 13.7 3.4
4 23.7 3.7 14 21.3 2.1
5 28.7 3.1 15 25.4 3.3
6 26.6 5.0 16 27.3 2.6
7 34.8 7.8 17 39.5 3.1
8 38.4 9.1 18 65.3
9 60.8 3.0
10 61.5 3.8
Fig. 2. Comparison of ELISA and Western blot analysis.
(A), a representative FPLC elution profile of human serum before () and after
({) sample pretreatment and subsequent ELISA of total and HMW adiponectin.
(B), comparison with Western blotting results (ratio of HMW adiponectin to total
adiponectin x total adiponectin).
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western blot analysis
We measured the relative distributions of adiponectin
isoforms in 56 human plasma samples by Western blot-
ting with nondenaturing and nonreducing gels. HMW
adiponectin concentrations in these samples were then
extrapolated by multiplying the percentage HMW adi-
ponectin values obtained by Western blotting by the total
adiponectin concentrations obtained with the Millipore
human adiponectin ELISA. The HMW adiponectin values
indirectly derived via Western blotting were then com-
pared with those obtained for the HMW Adiponectin
ELISA after sample pretreatment. HMW adiponectin con-
centrations obtained with these 2 different methods show
high correlation (y  0.77 x  0.15; r  0.96) (Fig. 2B). Of
note is that the apparent difference (approximately 23%)
in absolute values could be due to these 2 very different
methods and the possibilities of differential recognition
and/or different affinities of the antibodies used.
effect of body weight and sex
Mean (SE) values for total adiponectin, HMW adiponec-
tin, and percentage of HMW adiponectin (relative to total
adiponectin) in lean [mean BMI, 21.56 (1.85) kg/m2],
overweight [mean BMI, 26.79 (1.34) kg/m2], and obese
[mean BMI, 35.67 (5.13) kg/m2] individuals are shown in
Fig. 3A. As expected, concentrations of total adiponectin
were significantly decreased in overweight individuals
[10.75 (0.98) mg/L; P 0.05] and obese individuals [9.45
(0.51) mg/L; P 0.001], compared with lean individuals
[13.80 (1.08) mg/L]; however, the differences for HMW
adiponectin concentrations were even more pronounced
in overweight individuals [4.44 (0.55) mg/L; P 0.005]
and obese individuals [3.60 (0.32) mg/L; P 0.0001],
compared with lean individuals [7.06 (0.68) mg/L]. Sim-
ilarly, the differences in percentage of HMW adiponectin
were also more pronounced than for the total adiponectin
differences in comparisons of overweight individuals
[38.71% (2.55%); P 0.0002] and obese individuals
[35.44% (1.61%); P 0.000005] with lean individu-
als [50.48% (2.21%)]. The differences in HMW adiponectin
(P 0.0005) and percentage of HMW adiponectin (P
0.0005) were also more pronounced in the obese group
[mean BMI, 35.75 (5.13) kg/m2] than in the combined lean
and overweight groups [mean BMI, 24.32 (3.07) kg/m2],
compared with the differences for total adiponectin (P
0.005). The ratio of HMW adiponectin to total adiponec-
tin has previously been demonstrated to be higher in
female individuals than in male individuals (3, 15). Be-
cause of the disproportionately higher ratio of males to
females in the lean group than in the overweight and
obese groups, the weight-related decrease in HMW adi-
ponectin concentration may have been compromised due
to a suboptimal selection of the study population.
As shown in Fig. 3B with mean (SE) values, the
subpopulation of African American women [mean BMI,
29.74 (5.81) kg/m2; n  26] and men [mean BMI, 28.97
(7.78) kg/m2; n  35], featured more pronounced alter-
ations for HMW adiponectin [5.68 (0.64) mg/L and 3.63
(0.39) mg/L, respectively; P 0.02] and percentage of
HMW adiponectin [44.42% (2.38%) and 35.04% (2.26%),
respectively; P 0.01] than for total adiponectin [12.27
(1.08) mg/L and 9.54 (0.64) mg/L, respectively; P 0.05].
Analysis of the entire dataset of 54 female and 54 male
individuals revealed significantly higher values in fe-
males for HMW adiponectin (P 0.05), but not for per-
centage of HMW adiponectin (P 0.05) and total adi-
ponectin (P 0.05).
In a multivariate analysis with stepwise regression, the
best-fitting model included HMW adiponectin ( 
1.01; P 0.0001), sex (  3.5; P 0.01), and diastolic
pressure (  0.16; P 0.05). This model accounted for
20.5% of the variance in BMI (adjusted R2). Total adi-
ponectin was not a significant predictor and was thus left
out of the model.
gastric-bypass surgery
Fig. 4 summarizes the effects of weight loss on total,
HMW, and percentage of HMW adiponectin at 1, 3, 6, and
12 months after gastric-bypass surgery in 20 morbidly
obese adults (19 women and 1 man). Gastric-bypass
surgery produced appreciable weight loss and improved
insulin sensitivity in all of the patients (22 ). Before sur-
gery, the mean (SE) concentrations of total adiponectin
and HMW adiponectin in the morbidly obese patients
Fig. 3. Total adiponectin, HMW adiponectin, and percentage of HMW
adiponectin according to body weight and sex.
(A), values for lean (n  25), overweight (n  28), and obese (n  55)
individuals. *, P 0.05; **, P 0.001; , P 0.005; , P 0.0001; †, P
0.0002; ††, P 0.000005. (B), values for African American women (n  26)
and men (n 35). *, P0.05;, P0.02; †††, P0.01. Columns represent
the mean (SE).
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were 7.2 (0.5) mg/L and 2.2 (0.3) mg/L, respectively, and
the mean (SE) percentage of HMW adiponectin value was
28.1% (2.3%). Total adiponectin concentrations were un-
altered at 1 month after surgery [102.47% (7.66%) of
presurgery concentrations, P0.05] but were significantly
increased at 3 months [124.52% (9.02%), P 0.02], 6
months [141.3% (10.50%), P 0.001], and 12 months
[166.12% (11.44%), P 0.00002]; however, the changes in
HMW adiponectin were significantly more pronounced
than for total adiponectin at 1 month [147.00% (14.48%), P
0.0005], 3 months [173.65% (20.58%), P 0.002], 6
months [210.5% (23.44%), P 0.0002], and 12 months
[271.72% (30.67%), P 0.00002] after gastric-bypass sur-
gery. In addition, the changes in percentage of HMW
adiponectin were also more significant than for total
adiponectin at 1 month [134.61% (9.17%), P 0.00005], 3
months [136.08% (8.26%), P 0.0005], 6 months [146.81%
(7.64%), P 0.00001], and 12 months [160.74% (7.74%), P
0.0000005] after surgery.
Discussion
That adiponectin has an insulin-sensitizing effect (2–4)
and is an important biomarker for insulin sensitivity in
various pathophysiological conditions associated with
insulin resistance is well documented (1, 5–7). In addition,
the circulating adiponectin concentration seems to be a
good predictor of the progression of insulin resistance in
healthy and/or glucose-intolerant individuals (10, 11).
Therapeutic or dietary interventions intended to improve
insulin sensitivity are usually associated with increased
adiponectin concentrations (8, 9). Of the 3 distinct multi-
meric isoforms in the circulation, HMW adiponectin (12-
to 18-mers) is believed to be the most biologically active
(5, 12, 13). The HMW adiponectin concentration and/or
percentage of HMW adiponectin are reported to be a
better index of insulin sensitivity than total adiponectin
(14, 21).
Testing the importance of HMW adiponectin in vari-
ous metabolic states requires a simple, accurate, and rapid
methodology. A majority of the studies have fractionated
the different adiponectin multimers by size with gel
electrophoresis, gel filtration, and velocity gradient cen-
trifugation and then used immunoblotting with anti-
adiponectin antibody to recognize the multimers. These
time-consuming methods require experience in protein-
separation techniques. In addition, these methods are not
practical for analyzing several samples. Immunoassays,
particularly ELISA, can be an alternative. Currently, 2
different ELISAs are commercially available (23, 24). Blu-
her et al. (25 ) evaluated this HMW Adiponectin ELISA
(ALPCO Diagnostics), an RIA for total adiponectin, and
another ELISA (Mediagnost) to determine the best adi-
ponectin assay for predicting improvement in insulin
sensitivity after exercise in healthy individuals, those with
impaired glucose tolerance, and diabetic individuals.
These investigators found that the total adiponectin RIA,
not the HMW Adiponectin ELISA, was the better predic-
tor of insulin sensitivity. Another HMW Adiponectin
ELISA developed by Nakano et al. (24 ) uses an antibody
raised against HMW adiponectin but involves no enzyme
pretreatment of the sample. Although this adiponectin
ELISA is simple, it also measures the hexameric isoform to
some degree (24 ).
Our HMW Adiponectin ELISA method is simple,
rapid, and specific with respect to the multimeric (HMW)
isoform. After a simple enzyme pretreatment of the sam-
ple, the new ELISA recognizes predominantly the HMW
adiponectin isoform. This HMW Adiponectin ELISA
meets most of the analytical-robustness criteria of a good
immunoassay. In addition, the HMW adiponectin values
obtained with this method and with a more conventional
size-exclusion and Western blotting method are well
correlated (r 0.96) over a wide range of HMW adiponec-
tin concentrations; however, there is a 23% difference in
the absolute values, which is not surprising considering
the 2 very different methodologies.
The relevance of this new HMW Adiponectin ELISA is
demonstrated by comparing the values for HMW adi-
ponectin and total adiponectin in the context of BMI, sex,
and weight loss in morbidly obese patients. Obesity-
related changes were more apparent for HMW adiponec-
tin concentration and percentage of HMW adiponectin
than for total concentration when these variables were
evaluated for lean, overweight, and obese individuals
(26–28). Similarly, we noted larger differences between
men and women for HMW adiponectin concentration and
percentage of HMW adiponectin than for the concentra-
tion of total adiponectin (3, 15, 29); however, our studies
may have been compromised by confounding factors
introduced by a suboptimal control population. Gastric-
bypass surgery is an effective means of weight loss and
leads to improved insulin sensitivity (30 ). Similar to the
findings of Swarbrick et al. (22 ) with a different ELISA
(23 ), the present study also demonstrated a significant
increase in HMW adiponectin concentration and percent-
age of HMW adiponectin (but not for the concentration of
total adiponectin) at 1 month after gastric-bypass surgery,
when appreciable weight loss and an improvement in
Fig. 4. Total, HMW, and percentage of HMW adiponectin in morbidly
obese individuals after gastric-bypass surgery.
*, P 0.02; **, P 0.001; ***, P 0.00002; , P 0.002; , P 0.0005;
, P 0.0002; , P 0.00002; †, P 0.0005; ††, P 0.00001;
†††, P 0.000005; ††††, P 0.0000005. Columns (percentage of baseline
value) represent the mean (SE).
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insulin resistance are typically observed. The concentra-
tion of HMW adiponectin increased progressively at 3, 6,
and 12 months after surgery, along with further decreases
in body weight and insulin resistance (homeostasis model
assessment), and the increases were proportionately
greater than for total adiponectin concentrations.
In summary, we have developed a simple, robust, rapid,
and size-specific ELISA for measuring HMW adiponectin.
The results are comparable with those obtained with a
Western blotting method. More pronounced differences
were observed for HMW adiponectin than for total adi-
ponectin with respect to obesity, weight loss, and sex. This
assay may become a useful tool for high-throughput
analyses of HMW adiponectin and may facilitate further
elucidation of the importance of HMW adiponectin as a
biomarker for monitoring the progression and treatment
of diabetes and cardiovascular diseases.
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